

NATIONAL HEART FAILURE REGISTRY OF INDIA

Supported by



Indian Council of Medical Research

STANDARD OPERATING PROCEDURE

Principal investigators

Dr Harkrishnan S, SCTIMST Trivandrum

Dr Ajay Bahl, PGI Chandigarh

Dr Ambuj Roy, AIIMS New Delhi

Dr Animesh Mishra, NEIGRIHMS Shillong

Dr Jayesh Prajapathi, UN Mehta Ahmedabad

Dr Manjunath CN, Sri Jayadeva Bangalore

Dr Rishi Sethi, KGMU Lucknow

Dr Santanu Guha, MCH Kolkata

Dr Santosh Satheesh, JIPMER Pondicherry

National coordinating centre

Dr Harikrishnan S

PI and Coordinator - National Heart Failure Registry of India

Professor of Cardiology

Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum - 695011

Email: drharikrishnan@outlook.com | Phone: +91-9895-125-101 | +91-471-2524-457

Manas Chacko

Email: manaschacko@outlook.com | Phone: +91-890-7414-001

National Heart Failure Registry of India (NHFR INDIA)


Heart Failure (HF) is an important cardiovascular problem in India and its prevalence appears to rise. The data from the ICMR funded Trivandrum Heart Failure Registry shows that the Indian patients are younger by 10 years and majority of the burden is below 65 years of age compared to the west. We have no data on heart failure representative of the country.

Study objectives


To establish a Heart Failure Registry representative of the different regions of the country to study:

- 1. Etiology, Modes of presentation
- 2. Trends in management, outcomes
- 3. 90 day, 6 M and One year mortality
- 4. Readmission rate, causes


Duration




Follow-ups



Study process



Participating centres



A1.	Patient ID:		-	





A2. Date of recruitment: ____ / ___ / _____

N	ATION	IAL H	HEAI	RT FA	AILU	RE	REG	ISTF	RY O	F IN	DIA	- C	ATA	A CC	LLE	CTI	ON F	ORN	/ I
				lusion							-								
	Voc			missio			ite de	comp	ensat	ed he	art fo	ailur	e mus	t be s	creer	ned			
For	Yes	No No		Age <u>></u> Indiar															
all	Yes	No		Conse			he sti	ıdv											
A6.1				ı redu					(HFrE	F)									
	Yes	No	-	1a Syn						<u>, </u>									
	Yes	No	A6.	1b LVE	F < 40	%													
A6.2	Heart	failur	e with	n mid-	d-range ejection fraction (HFmrEF)														
	Yes	No			Symptoms <u>+</u> Signs														
	Yes	No			LVEF 40% - 49%														
A6.3		rrt failure with preserved ejection fraction (HFpEF)																	
	Yes	, , , = 0																	
	Yes	No	-				art dic	-25A	hv ect	10 (I V	/H or	ΙΔF) or l	V dia	stolic	dvefi	unctio		
	Yes																		
A6.4		Isolated right heart failure																	
	BASELINE DATA (At the time of current admission)																		
B1	Hospita	al num													<u> </u>				
B2	Full nar	me of	the pa	atient:															
	Age in completed years B4 Date of birth																		
В3		•		•									_						
								1				D	D	M	M	Υ	Υ	Υ	Υ
B5	Sex	1. Ma	le		2. Fe	mal	е												
В6	House/	Flat na	ame d	r num	ber														
B7	Street/	localit	y/sec	tor															
B8	Post of	fice																	
B9	District																		
B10	State/L	JT																	
B11	PIN Cod	de [
B12	ADHAA	AR No																	
B13	Patient	's mok	oile ph	none n	umbe	r	I	0											
B14	Patient	's seco	ondar	y phon	e num	ber	•												<u></u>
214								0											
B15	Relative phone		_	iver's				0											
B16	Relativ		_		er			0											

Participant ID	:	-	

B17		number o <i>r illiter</i>	of years ate)	of educ	ation co	omplete	ed									
B18	Date o	f confir	mation o	f HF		D	D	M	N	Л	Υ	Υ	Υ	Υ		
	Signs a	nd sym	ptoms: (7	Tick all c	applicat	ole)										
			Sympt	oms								Signs				
	B19.1	B19.2	B19.3	B19.4	B19.5	B19.6	B19.7	7 B1	9.8	B19.	9 B	19.10	B19.1	1	B19.12	B19.13
B19	Dyspnoea / PND / Orthopnoea	Fatigue /↓effort tolerance	H/o oedema	Palpitation	Angina	Ascites	Lung rales	Pleural effusion	/ascites	Ψλι√Ρ		S3	Dependent oedema		Hepatomegaly	Cardiomegaly
	Type of	f heart f	ailure	•							•	•		•		
B20		with red		2. H	F with n	nid-rang	e EF	3. HI	Fwith	h pres	serve	d EF	4. Isc	late	d right h	eart
	(<40%)		(40-	49%)			(<u>></u> 50)%)				failur	е		
B21	Full dia	gnosis:	(to be wi	rittenj												
	Etiolog	y of HF	(Tick all	applica	ble)		1		1	T						
	B22.1	B22.2	B22.3	B22.4	B22.5	B22.	6	B22.7	B22	2.8	B22.9	B22	.10 E	322.11	L E	322.12
B22	Ischemic Heart Disease	Rheumatic heart disease	Non rheumatic valvular heart disease	Dilated cardio myopathy	Hypertrophic	Restrictive cardio	myopathy	Congenital heart disease	Right heart	failure	Peripartum cardio myopathy		Myocardius	Infective		rs Specify
	Dick fac	ctors /T	ick all ap	nlicable	.)	•	•		•			•			1	
	B23.1	B23.		B23.4	B23.5	B23.6	B23.7	B23.8	B23.9	9 B2	23.10	B23.11	B23	3.12	B2:	3.13
B23	Tobacco use (current or ex)		(current or ex) Hypertension	Diabetes mellitus	Atrial Arrhythmia	Hypothyroidism Hypothyroidism	Hyperthyroidism	H/o Stroke/ TIA	QdO		3.10 QXD	Chemotherapy / Drugs / radiation	-	12	Others S	

Participant ID:	-	

B24	Previous HF admission	n		1. Y	es			2.	No											
B25	If Yes, last HF admiss	sion	date	<u>;</u>			D		D	M	M	Υ	Υ		Υ	,	Y			
B26	Number of previous	HF a	admi	issio	ns ir	the	e las	t 12	mo	nths ex	cludin	g curr	ent a	admi	ssio	n				
	Procedures performe	ed pr	evic	ously	or i	n th	is ac	dmis	sio	n <i>(tick a</i>	ıll appi	icable	ana	ente	er th	ne do	ate)			
	Procedure	Da	te				1	1		Proce	edure		Da	ite	1	1	1	1		1
	B27.1 CAG 1	D	D	M	M	Υ	Υ	Υ	Υ	B27.8	MVR/	AVR	D	D	M	M	Υ	Υ	Υ	Υ
	B27.2 CAG 2	D	D	M	M	Υ	Υ	Υ	Υ	B27.9	CRT-I)	D	D	M	M	Υ	Υ	Υ	Υ
B27	B27.3 PCI 1	D	D	M	M	Υ	Υ	Υ	Υ	B27.1	O AICI)	D	D	M	M	Υ	Υ	Υ	Υ
	B27.4 PCI 2	D	D	M	M	Υ	Υ	Υ	Υ	B27.1	1 PPI		D	D	M	M	Υ	Υ	Υ	Υ
	B27.5 BMV/BAV 1	D	D	M	M	Υ	Υ	Υ	Υ	B27.1	2 Speci	fy 1	D	D	M	M	Υ	Υ	Υ	Υ
	B27.6 BMV/BAV 2	D	D	M	M	Υ	Υ	Υ	Υ	B27.1	3 Speci	fy 2	D	D	M	M	Υ	Υ	Υ	Υ
	B27.7 CABG	D	D	M	M	Υ	Υ	Υ	Υ	B27.1	4 Speci	fy 3	D	D	M	M	Υ	Υ	Υ	Υ
B28	Current admission da	ate	D		D	N	1	M		Υ	(Υ	Υ							
B29	NYHA Class C	lass	ı	I	C	lass	s II			Class II	I	Cl	ass l'	V						
B30	Heart rate (Beats pe At admission	r mir	nute	:)																
B31	SBP (mm of Hg) At admission							•		B32 D At adm	-	m of H	lg)							
B33	JVP 1. Elevated	2	2. No	ot el	evat	ed				B34 Ar arrhyth	-					1. Y	'es	2.	. No	
B35	Peak Trop-T ng/L	•				-	Posi Neg		2	B36 Pe Trop-I ng/L									sitiv gativ	
B37	Hb (g/dl) (lowest)				•					B38 Se mg/dl (ne				•			
B39	Serum urea mg/dL (highest)									B40 BU mg/dL		st)								
B41	Serum Na (mEq/L) at admission									B42 Se (mEq/L)			n							
B43	BNP pg/ml At admission									B43a N At adm	NT Pro	BNP p		ıl						
B44	BNP pg/ml								$\dagger \dagger$	B44a N	NT Pro		g/m	ıl						青
B45	At discharge ECG - Rhythm		<u>_</u>	1. SR		2	2. AF	1	<u>- </u>	At disc		Othe	rs Sp	ecify	<u>'</u> ':				<u>+</u>	
	(tick all applicable)										1									
B46		1.	Nori	mal		2.	LB	BB		3.	RBBE	3	4	. IV	/CD					
B47	Echo - EF %									B48 RV mm of										

Participant ID:	-		

B49	LV diastolic dysfu	ınction	1. 1	No		2. Mild		3. I	Modera	te	4. Seve	ere
B50	MR		1. N	No		2. Mild		3. ſ	Moderat	te	4. Seve	ere
B51	Echo - any other	descriptiv	e finding		·					·		
B52	Ventilation durin	g current	admissio	n		1.	No		2. NI	V	3. Inva	asive
B53	Mechanical circu during current ac		port	1.	No		2.	IABP		3.	VAD	
B54	Weight at admission in Kgs					B55 W dischar	_				•	
B56	Height in cm											
B57	Other investigation	on Specify	/ (TSH, HI	bA1c)								
	MEDICATION (7	Tick all ap	plicable d	drugs)	•		T					
	Drugs (Write generic nam	ne and dos	e for 58,5	9,60)	Admi ssion	Disch arge	Spec	cify reaso	n for no	t prescril	oing 58,5	59,60
B58	Beta-blocker Spe	cify:			Dose	Dose						
B59	ACEI / ARB Specij	fy:			Dose	Dose						
B60		plerenon pironolact			Dose	Dose						
B61	Diuretic - Thiazid	e					Intra	avenous	drugs (Ti	ck	During	
B62	Diuretic - Loop di	uretic					-	e than or				alization
B63	Diuretic - Others						B75	Ер	inephrii	ne		
B64	Digoxin						B76	No	orepinep	hrine		
B65	ARNI						B77	Do	pamine)		
B66	Nitrates						B78	Do	butami	ne		
B67	Other vasodilato	r Specify					B79	М	ilrinone			
B68	Ca channel block	er					B80	Le	vosimer	ndan		
B69	Heparin/LMWH						B81	N٦	ΓG			
B70	OAC						B82	Di	uretic			
B71	Ivabradine						B83	Other c	ardiac d	rugs (O	ral/IV)	
B72	Pulmonary vasod	lilator										
B73	Antiplatelet											
B74	Antibiotic											
B84	Outcome 1.	Discharge	9	2.	Death			3. Refe	rred			
B85	If death, cause of	fdeath	1. SCD	2. Pum	p failure	3. MOI	DS 4	l. Others	-Specify:			
B86	Date of discharge	e/death/re	eferral		D	D M	N	1 Y	Υ	Υ	Υ	

Patient ID: ____ - ___ ___





	NHFR INDIA F	OLL	ow-u	JP I	FORM				
C1	Follow-up visit Three	om s	nths	Si	ix months		One	year	
C2	Date of follow-up visit	M	Υ	Υ	Υ	Υ			
СЗ	Type of follow-up visit: 1. Clinic visit 2. Telep 4.By proxy	phon	ic follo	w-u	p 3. Med	ical rec	ord sea	arch	
C4	Status at the time of follow-up: 1.Alive 2. Di	ied	3. Lost	to f	ollow-up				
C5	If died, died in the hospital? 1. Yes		2	. No) 3	3. Unkn	own	1	
C6	If died, cause of death? 1. CVD	2	. Non-0	CVD		Unkno			
C7	If CVD, specify 1. SCD 2. Pump failure 3	3. MO	DS 4.	Stro	oke 5 CK	D 6. O	thers-S	Specify:	
C8	If died, date of death (most accurate/approximate))	D	M	M	Y		Y	
C9	If died, please narrate the event								
C10	If lost to follow-up, date last known alive	D	D	N	/I M	Υ	Υ	Y	
C11	Readmission since discharged 1. Yes 2. from the recruited hospital	. No		•	es, numbe ged from t				
C13	Procedures since the last follow-up with dates	S	·						
C14	NYHA Class I Class II Class III Clas	s IV	C15	Ech	o - EF %				
C16	Heart rate C17 SBP					C17a D	BP		
C18	BNP pg/ml		C	18a I	NT Pro BN	P pg/m	I		
C19	Serum creatinine mg/dl ·		C Kg		Veight in				
	MEDICATION (Tick all applicable drugs) Write	e gen			nd dose for	21,22,2	!3		
C21	Beta-blocker Specify:	Dose			C24 Diure	etic			
C22	ACEI / ARB Specify:	Dose			C25 ARNI				
C23	Aldosterone Eplerenone blocker Spironolactone	Dose			C26 Digo	kin			
Moris	sky, Green and Levine medication adherence sca	ale		J.					
	Question		Strong		Agree	Disag		Strongly disagree	Don't know
C27	I sometimes forget to take my medicines.		5 - 5					0	-
C28	I am sometimes careless about taking my medicines.								
C29	When I feel better, I sometimes stop taking medicines.	У							
C30	If I feel worse when I take my medicine, sometimes I stop taking it.								

Please be very careful while filling the data collection form and consult the Principal investigator (PI) or Co-Principal investigator (Co-PI) in case you have doubts about filling. You are welcome to contact Nodal Centre / National Coordinating centre for any clarification. The incorrect data will ruin the study.

DATA COLLECTION FORM

A1 Patient ID - Patient ID has 2 parts first 2 digit represent Centre number next 3 digit represent patient serial number (centre ID provided by coordinating centres)

A2 Date of Recruitment - Date of recruitment must enter in dd/mm/yyyy format

Inclusion criteria checklist

A3 The patient should be an Indian citizen and age more than 18 years for recruitment
A6 Enter type of heart failure

- Patient should have symptoms with or without signs of heart failure
- Enter type of heart failure based on EF.
- Structural heart disease by echo (LVH or LAE) or LV diastolic dysfunction should be there for HFpEF

DIAGNOSTIC CRITERIA

- 1. Admission with clinical diagnosis of HF and the discharge diagnosis should also confirm HF.
- Echocardiography confirmation of diagnosis of structural Heart Disease.
 (Demonstration of an underlying cardiac cause is central to the diagnosis of HF. ESC 2016)
- 3. HFrEF EF < 40%
- 4. HFmrEF EF 40-49%
- 5. HFpEF EF >50%
 - A. Elevated BNP / NT Pro BNP -

- B. With either of the following
 - Structural Heart Disease by echo Valvular stenosis or regurgitation,
 LVH(left ventricular hypertrophy) or LAE (Left atrial enlargement)
 - 2. Diastolic dysfunction

(BNP = B-type natriuretic peptide; HF = heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LAE = left atrial enlargement; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NT-proBNP = N-terminal pro-B type natriuretic peptide)


Minimum three out of four conditions should satisfy for the diagnosis of LV diastolic dysfunction in subjects with normal LVEF

- > Average E/e' > 14
- > Septal e' velocity < 7 cm/s or Lateral e' velocity <10 cm/s
- > TR velocity > 2.8 m/s
- ➤ LA volume index >34ml/m2

Two-dimensional and Doppler methods for assessment of LV diastolic function

Variable	Acquisition	Analysis		
Peak E-wave velocity (cm/sec)	1. Apical four-chamber with colour flow imaging for optimal alignment of PW Doppler with blood flow. 2. PW Doppler sample volume (1–3 mm axial size) between mitral leaflet tips. 3. Use low wall filter setting (100–200 MHz) and low signal gain. 4. Optimal spectral waveforms should not display spikes or feathering.	Peak modal velocity in early diastole (after ECG T wave) at the leading edge of spectral waveform		
Peak A-wave velocity (cm/sec)	1. Apical four-chamber with colour flow imaging for optima alignment of PW Doppler with blood flow 2. PW Doppler sample volume (1–3 mm axial size) between mitral leaflet tips. 3. Use low wall filter setting (100–200 MHz) and low signal gain. 4. Optimal spectral waveforms should not display spikes or feathering.			
Mitral E/e0	E and e' velocities	MV E velocity divided by mitral annular e0 velocity		
LA maximum volume index (mL/BSA)	 Apical four- and two-chamber: acquire freeze frames 1–2 frames before MV opening. LA volume should be measured in dedicated views in which LA length and transverse diameters are maximized. 	Method of disks or area-length method and correct for BSA. Do not include LA appendage or pulmonary veins in LA tracings from apical four- and apical two-chamber views.		

Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2016;29(April (4)):277–314.



Doppler echocardiographic determination of systolic pulmonary artery pressure (SPAP). Spectral continuous-wave Doppler signal of tricuspid regurgitation (TR) jet is used to derive the SPAP. The TR jet velocity indicates the right ventricular (RV) − right atrial (RA) pressure gradient. The SPAP is derived as the sum of the estimated RA pressure (RAP) and the peak pressure gradient between the peak right ventricle and the right atrium, as estimated by application of the modified Bernoulli equation (4 V2 where V is the velocity of the TR jet) to peak velocity represented by the tricuspid regurgitation Doppler signal.9 The RAP was estimated from the inferior vena cava diameter. If the IVC was ≤21 mm and the deep inspiratory collapse ("sniff test") was >50%, RAP was estimated to be 3 mmHg; if the diameter was >21 mm and the collapse <50%, RAP was estimated as 15 mmHg; in intermediate cases, a value of 8 mmHg was assigned.9 In this example, SPAP is estimated at 92 + central venous pressure, or 100 mmHg, if RAP is assumed to be 8 mmHg.

Symptoms and signs typical of heart failure

Symptoms	Signs
Typical	More specific
Breathlessness Orthopnoea Paroxysmal nocturnal dyspnoea Reduced exercise tolerance Fatigue, tiredness, increased time to recover after exercise Ankle swelling	Elevated jugular venous pressure Hepatojugular reflux Third heart sound (gallop rhythm) Laterally displaced apical impulse
Less typical	Less specific
Nocturnal cough Wheezing Bloated feeling Loss of appetite Confusion (especially in the elderly) Depression Palpitations Dizziness Syncope Bendopnea ⁵³	Weight gain (>2 kg/week) Weight loss (in advanced HF) Tissue wasting (cachexia) Cardiac murmur Peripheral oedema (ankle, sacral, scrotal) Pulmonary crepitations Reduced air entry and dullness to percussion at lung bases (pleural effusion) Tachycardia Irregular pulse Tachypnoea Cheyne Stokes respiration Hepatomegaly Ascites Cold extremities Oliguria Narrow pulse pressure

Table 12.2 Definitions of the terms used in Section 12 on acute heart failure

Term	Definition
Symptoms/signs of congestion (left-sided)	Orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales (bilateral), peripheral oedema (bilateral).
Symptoms/signs of congestion (right-sided)	Jugular venous dilatation, peripheral oedema (bilateral), congested hepatomegaly, hepatojugular reflux, ascite symptoms of gut congestion.
Symptoms/signs of hypoperfusion	Clinical: cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. Laboratory measures: metabolic acidosis, elevated serum lactate, elevated serum creatinine. Hypoperfusion is not synonymous with hypotension, but often hypoperfusion is accompanied by hypotension.
Hypotension	Systolic BP <90 mmHg
Bradycardia	Heart rate <40 bpm
Tachycardia	Heart rate >120 bpm
Abnormal respiratory effort	Respiratory rate >25 breaths/min with use of accessory muscles for breathing, or respiratory rate <8 breaths/min despite dyspnoea.
Low O ₂ saturation	O ₂ saturation (SaO ₂) <90% in pulse oximetry Normal SaO ₂ neither excludes hypoxaemia (low PaO ₂) nor tissue hypoxia.
Hypoxaemia	O ₂ partial pressure (PaO ₂) in arterial blood <80 mmHg (<10,67 kPa) (blood gas analysis).
Hypoxaemic respiratory failure (type I)	PaO ₂ <60 mmHg (<8 kPa)
Hypercapnia	CO ₂ partial pressure (PaCO ₂) in arterial blood >45 mmHg (>6 kPa) (blood gas analysis).
Hypercapnic respiratory failure (type II)	PaCO ₂ >50 mmHg (>6,65 kPa).
Acidosis	pH <7.35
Elevated blood lactate	>2 mmol/L
Oliguria	Urine output <0.5 mL/kg/h

 $BP = blood\ pressure; bpm = beats\ per\ minute; PaCO_2 = partial\ pressure\ of\ carbon\ dioxide\ in\ arterial\ blood; PaO_2 = partial\ pressure\ of\ oxygen\ in\ arterial\ blood; SaO_2 = oxygen\ saturation.$

Typically, symptoms and signs of AHF reflect fluid overload (pulmonary congestion and/or peripheral oedema) or, less often, reduced cardiac output with peripheral hypoperfusion. Since the sensitivity and specificity of symptoms and signs are often not satisfactory, careful clinical evaluation needs to be followed by additional investigations

BASELINE DATA

Demographic Data

B1. Hospital number: Enter correct hospital number for future reference

B2. Name of the patient : Write patient's full name (CAPITAL LETTER)

B3. Date of birth (dd-mm-yyyy) : day-month-year format, eg:01-01-2019

B4. Age : in completed years

B5. Sex : Male/Female

B6. House Name & House Number : Enter correct house name and house number

B7. Street & locality : Exact place name and location

B8. Post office : Name of the post office

B9. District : Name of the district where the patient is staying

B10. State : Name of the state or UT where the patient is living

B11. Pin Code : Enter the correct pin code number

B12. ADHAAR No : Enter the correct ADHAAR No

B13. Patient Mobile Number : Must be correct with 10 digits

B14. Patient's secondary phone number : Patient second contact number

B15. Relative's phone number : Patient's close relative's phone number

B16. Relative's secondary phone number : Patient's close relative's second contact number

B17. Years of education completed: Enter exact years of schooling completed, Enter zero for illiterate

B18. Date of confirmation of HF : First date of heart failure diagnosis as clinically

B19 Symptoms

Dyspnea –Difficult or Labored breathing

PND - **Paroxysmal nocturnal dyspnea** or **paroxysmal nocturnal dyspnoea** (PND) refers to attacks of severe shortness of breath and coughing that generally occur at night. It usually awakens the person from sleep, and may be quite frightening

Orthopnea -orthopnea is shortness of breath (dyspnea) that occurs when lying flat

Fatigue - Feeling of tiredness

↓ effort tolerance - inability or decreased ability to perform physical exercise

H/O Edema- pedal edema or abdominal distension

Lung rales: presence of Crepitations, if chest is clear mention as no Rales

Pleural effusion/ascites: collection of fluid in the pleural cavity / abdominal cavity (as per doctor's notes)

JVP: Jugular venous pressure please mention if it is elevated or not, if available mention the height in

centimeters (as per doctors notes)

Edema: as per physical examination

Hepatomegaly/cardiomegaly/S3/murmur: as per physical examination by doctors

B21. Admitting diagnosis: please mention complete diagnosis of the patient, written in the case file

by the doctors

B22. Etiology of heart failure: (please tick whichever applicable)

Ischemic heart disease - Coronary heart disease is a common term for the buildup of

plague in the heart's arteries that could lead to heart attack

Rheumatic heart disease - Rheumatic heart disease (RHD) is damage to one or more heart

valves that remains after an episode of acute rheumatic fever (ARF) is resolved. It is caused by

an episode or recurrent episodes of ARF

Non rheumatic valvular heart disease- Heart valve problems can result from disease,

infection (endocarditis) or a defect present at birth. When the valves don't open or close

completely during each heartbeat, the heart muscle has to pump harder to keep the blood

moving. If the workload becomes too great, heart failure results.

Dilated cardio myopathy - DCM is a condition in which the heart's ability to pump blood is

decreased because the heart's main pumping chamber, the left ventricle, is enlarged and

weakened.

Hypertrophic cardio myopathy - Hypertrophic cardiomyopathy (HCM) is a disease in which

the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened

heart muscle can make it harder for the heart to pump blood.

Restrictive cardio myopathy - (RCM) is a form of cardiomyopathy in which the walls of the

heart are rigid (but not thickened). Thus the heart is restricted from stretching and filling with

blood properly

17

Congenital heart disease - A congenital heart defect (CHD), also known as a congenital heart anomaly or congenital heart disease, is a problem in the structure of the heart that is present at birth

Right heart failure - When the **right** side loses pumping power, blood backs up in the body's veins. This usually causes swelling or congestion in the legs, ankles and swelling within the abdomen such as the GI tract and liver (causing ascites)

Peripartum cardiomyopathy - Peripartum cardiomyopathy (PPCM), also known as postpartum cardiomyopathy, is an uncommon form of heart failure that happens during the last month of pregnancy or up to five months after giving birth. PPCM is a dilated form of the condition, which means the heart chambers enlarge and the muscle weakens

Myocarditis: Inflammation and damage of the heart muscle.

Others – Specify – eg. Severe lung disease, Diabetes, severe anemia, hyperthyroidism, arrhythmia or dysrhythmia etc

B23. Risk factors (tick all applicable)

Tobacco : Current or Ex (previous history)

Alcohol : Current or Ex (previous history)

HTN : Hypertension: yes / no

DM : Diabetes Mellitus: yes/no

Atrial arrhythmias : Afib (atrial fibrillation)/AF (atrial flutter) /no

Thyroid function: yes/no. Hypo/Hyper/Euthyroid

Stroke/TIA : yes/no (stroke: neurological deficit persisting more than

24hrs/ TIA: trans ischemic attack: neurological deficit recovered less than 24 hrs without persistent deficit)

COPD : chronic obstructive pulmonary disease yes/no

CKD : chronic kidney disease yes/no

Chemotherapy/drugs: if treated or treating with these drugs yes/no (Anticancer drugs)

B24 Previous HF admission: if applicable please mention yes /no

B25 Last HF admission date: if histories of previous hospitalization with HF mention the date

B26 No: of admissions in last 12 months with HF: mention if occurred

B27 Procedures performed previously or in this admission (tick all applicable and enter date)

CAG: Coronary Angiogram

PCI: percutaneous coronary intervention/PTCA/stenting/coronary angioplasty

BMV/BAV: Balloon Mitral Valvotomy /Balloon Atrial Valvotomy

CABG: Coronary arteries bypass grafting

MVR/AVR: Mitral Valve Repair/Replacement /Aortic Valve Repair/Replacement

CRT-D/CRT-P: cardiac re-synchronization therapy/triple chamber pacing/Defibrillation/pacing

AICD: implantable cardioverter defibrillator

PPI: permanent pacemaker implantation

Any Other-Specify: Eg- ASD device closure, aneurysm repair, TAVI, TAVR, any other major surgeries

Clinical features: ECG, LABs &ECHOCARDIOGRAPHY (mark NA if not available)

B28 Admission date – dd/mm/yyyy format

B29 NYHA Class - NEWYORK HEART ASSOCIATION functional class for symptoms (I, II, III, IV)

B30 HR: heart rate (bpm)

B31 SBP: systolic blood pressure (mm of Hg)

B32. DBP: Diastolic blood pressure (mm of Hg)

B33. JVP : Jugular Venous Pressure elevated or not

B34. Any VT: any Ventricular arrhythmia (Yes/No)/ Ventricular tachycardia

B35, 36. Enter peak Trop T or Trop I value

B37. Hb (g/dl): Enter the haemoglobin value

B38. Highest serum creatinine value during current hospital admission

B39. Highest urea or BUN value during current hospital admission

B41. Serum Na: mention the serum sodium level (mEq/L) first value at current admission

B42. Serum K: mention the serum potassium level (mEq/L) first value at current admission

B43. BNP: mention whether it is BNP - B-type natriuretic peptide

B44. NT Pro BNP: Mention N terminal Pro B-type natriuretic peptide value

B45. ECG Rhythm (SR/AF/Paced): Sinus rhythm/Atrial fibrillation/paced rhythm

B46. QRS complex- LBBB (left bundle branch block)/RBBB (right bundle branch block)/ Normal/IVCD-Intraventricular conduction delay

•

B47 ECHO- EF: ejection fraction (%)

B48. RVSP: right ventricular systolic pressure

B49. Diastolic dysfunction – Mild/Moderate/Severe

B50. MR : mitral regurgitation: mild (1-2+)/moderate (3+)/severe (4+)

B51. Echo-any other descriptive finding –

B52. Mechanical Ventilation - No/Noninvasive (BiPAP or CPAP) /Invasive

B53. Mechanical Circulatory Support - No/Intra-Aortic Balloon pump/Ventricular Assist Device

B54. Weight –During Admission time (Kgs)

B55. Weight -At the time of discharge

B56. Height in cm –Mention Height in centimetre

B57. Other investigation Specify (TSH, HbA1c) – Mention Thyroid stimulating hormone level, Glycosylated haemoglobin level

MEDICATIONS ADVISED (Mention Yes-1 No-0, write 99 if any medication stopped)

During admission and at the time of discharge

Specify generic name and dose for 58, 59 & 60

B58. Beta-blocker - metoprolol, carvedilol, bisoprolol, nebivolol / atenolol and dose

B59. **ACEI** (angiotensin converting enzyme inhibitors): ramipril, enalapril,lisinopril, Fosinopril and dose

ARB (angiotensin receptor blockers): losartan, telmisartan, valsartan, Olmesartan and dose

B60 Aldosterone blockers: spironolactone, eplerenone and dose

Specify Yes or No

B61. Diuretics: lasix, (frusemide) torsemide, hydrochlorothiazide, indapamide, Chlorthalidone

B64. Digoxin (lanoxin/dixin)

B65. ARNi-Angiotensin II Receptor Blocker Neprilysin inhibitor, eg: Vymeda/Azmarda/Cidmus

B66. Nitrates

B67 Other vasodilators: *nitrates, hydrallazine*

B68 Calcium channel blockers

B69. Heparin/, LMWH-Heparin sodium/Low molecular weight Heparin

B70. OAC (oral anticoagulant): Warf, Dindevan(Phenindione), Acitrom(Nicoumalone)

B71. Ivabradine First selective sinus node inhibitor eg:coralan ,Ivabrad, Ivabeat

B72. Pulmonary vasodilators

B73 Inotropes: (dopamine, dobutamine, adrenaline, nor adrenaline, levosimendan)

B79. IV nitroglycerin

B80. IV diuretics

B81 Other drugs: which are used for the patient other than the above.

B83 Outcome: Discharge/Death/Referred (Apply tick mark if any one applicable)

 ${\tt B84\ Cause\ of\ Death: SCD\ (Sudden\ cardiac\ death),\ Pump\ failure,\ MODS-multi-organ\ dysfunction}$

syndrome) / Non cardiac

B85 Date of discharge : dd/mm/yyyy format

NHFR INDIA FOLLOW-UP FORM

C1 Follow-up visit: Enter the number of followup visit

C2 Date of follow-up visit: Enter the date of followup visit. It can be data of OPD visit or date of telephonic followup

C3 Enter the type of followup visit

C4 Enter lost to followup if you are unable to contact the patient by all possible ways.

C5 Whether the patient died in the hospital or not.

C6 Cause of death: If death is due to accident, suicide, natural disasters, or not due to heart disease like cancer then mark as non-CVD.

C7 Specify the cause of death.

METOPROLOL

METOLAR-XR

C8 Date of death: <u>This should be most accurate.</u> If you are not able find out exact date, then enter most approximate date like first week, second weed, middle of the month, end of the month. If you don't know the date and know only month **do not enter** like 01-Month-Year **for all patients**. Try to find out most approximate date. Enter 7-mm-yyyy for first week, 15-06-yyyy for the middle of the month if it is June etc.

C9 Please narrate the event briefly for cause of death validation.

C10 If lost to follow-up, date last known alive: This can be obtained from a third party also (By proxy).

C11 Readmission since discharged from the recruited hospital yes or no.

C12 Number of readmissions since discharged from the recruited hospital. It is not since last followup. IT IS SINCE THE RECRUITMENT.

Modified Morisky Medication Adherence Scale: Ask the questions to the patient in regional language and mark the responses.

GUIDELINE FOR MEDICINES AND DOSAGES COMMONLY USED

DOSAGE

BETABLOCKERS

BETALOC	25MG,50MG,100MG
BETAONE-XL	12.5MG,25MG,50MG
KIMET –XL	12.5MG,25MG,50MG
LOPRESOR	25MG,50MG
METAPRO	25MG,50MG
METAPRO –XL	50MG
METOCARD – XL	12.5MG,25MG,50MG
METOLAR	12.5MG,25MG,50MG

25MG,50MG

TOPOL –XL 25MG,40MG,100MG

VIVALOL-XL 25MG,50MG

CARVEDILOL

CARDIVAS 3.125MG,6.25MG,12.5MG,25MG CARVEDIL 3.125MG,6.25MG,12.5MG,25MG CARVETREND 3.125MG,6.25MG,12.5MG25MG CARVIL 3.125MG,6.25MG,12.5MG,25MG

CARVIMED 3.125MG,12.5MG CASLOT 3.125MG,6.25MG CEVAS 3.125MG,12.5MG

ORICAR 3.125MG,6.25MG,12.5MG,25MG

BISOPROLOL

BISOPROLOL 2.5MG - 10MG

BISBETA 5MG

CORBIS 2.5MG,5MG,10MG

ZABESTA 2.5MG,5MG

CORBIS-H

BISOPROLOL FUMARATE 2.5MG+HYDROCHLOROTHIAZIDE 6.25MG

LODOZ

BISOPROLOL FUMARATE 2.5MG+HYDROCHLOROTHIAZIDE 6.25MG

ZABESTA - XLO

BISOPROLOL FUMARATE2.5MG+HYDROCHLOROTHIAZIDE 6.25MG

ATENELOL

ATENELOL 25MG,100MG

AGLOTEN 50MG

ANOL 25MG,50MG

ATBETA 50MG

ATCOM 25MG,50MG

ATEN 25MG,50MG,75MG,100MG

ATENEX 25MG,50MG,100MG ATENOVA 25MG,50MG,100MG

ATEPRES 50MG

ATPARK 25MG,50MG,100MG BETA 25MG,50MG,100MG BETACARD 25MG,50MG,100MG BIDUTEN 25MG,50MG,100MG

CARDEN 25MG,50MG

CATENOL 25MG,50MG,100MG

HIBESOR 25MG,50MG
HYTEN 25MG,50MG
PRESTEN 25MG,50MG
TEFIFIN 25MG,50MG

TENOLOL 12.5MG,25MG,50MG,100MG

TENOREX 2.5MG25MG,100MG

TENORMIN 25MG,50MG,100MG **ZIBLOK** 12.5MG,25MG,50MG,

ATEN-D ATENELOL 50MG + INDAPAMIDE 2.5MG

ATEN-H ATENELOL 50MG + HYDROCHLOROTHIAZIDE 12.5MG ATENOVA-H ATENELOL 50MG + HYDROCHLOROTHIAZIDE 12.5MG BETACARD-H ATENELOL 50MG + HYDROCHLOROTHIAZIDE 12.5MG TENORIC-25 ATENELOL 25MG + CHLORTHALIDONE 12.5MG

TENORIC-50 ATENELOL 50MG + CHLORTHALIDONE 12.5MG

ANGIOTENSIN RECEPTOR BLOCKERS (ARB)

LOSARTAN

ACTILOP 25MG,50MG **ALSARTAN** 25MG,50MG **AARTAN** 25MG,50MG **ARBLOS** 25MG,50MG **ANGIZAAR** 25MG,50MG **ASORTAN** 25MG,50MG **COVANCE** 25MG,50MG CZAR 25MG,50MG **GIFTAN** 25MG,50MG

HYPART 50MG

LARA 25MG,50MG LOPASSIUM 25MG,50MG **LOSAVIK** 25MG,50MG **LOSACAR** 25MG,50MG **LOSAGARD** 25MG,50MG LOSAMAX 25MG,50MG

LOSAR 25MG,50MG,100MG

LOSKER 50MG

LOSATEC 25MG,50MG LOSATRUST 25MG,50MG LOSCARD 25MG,50MG **ZAART** 25MG,50MG

NUSAR-ATN ATENELOL 50MG + LOSARTAN K 50MG ANGIZAAR - AT LOSARTAN K50MG + ATENELOL 50MG LOSAR-BETA LOSARTAN K50MG + ATENELOL 50MG

IRBESARTAN DOSAGE

IROVEL 150MG,300MG **XARB** 150MG,300MG

IROVEL-H HYDROCHLOROTHIAZIDE12.5MG + IRBESARTAN 150MG XARB-H HYDROCHLOROTHIAZIDE12.5MG + IRBESARTAN 150MG

CANDESARTAN

CANDESAR 4MG,8MG CANTAR 4MG,8MG

CANDESAR-H CANDESARTAN16MG + HYDROCHLOROTHIAZIDE12.5MG

OLMESARTAN

CULMI 10MG,20MG
OLMAT 20MG,40MG
OLMAX 20MG,40MG

OLMESAR 10MG,20MG,40MG
OLMY 10MG,20MG,40MG
OLMEZEST 5MG,10MG,20MG,40MG

OLSAR 10MG,20MG,40MG

OLMAT-H OLMISARTAN20MG+ HYDROCHLOROTHIAZIDE 12.5MG

TELMISARTAN

TELMAR 20MG,40MG,80MG
TELMA 20MG,40MG,80MG
TELMISART 20MG,40MG,80MG

TELMA-H TELMISARTAN 40MG+HYDROCHLOROTHIAZIDE 12.5MG

OLMY 10MG,20MG,40MG

ACE INHIBITORS

LISNOPRIL DOSAGE
ACEBITOR 5MG,10MG

ACINOPRIL 2.5MG,5MG,10MG
BIOPRIL 2.5MG,5MG,10MG
HIPRIL 2.5MG,5MG,10MG
LINVAS 2.5MG,5MG,10MG
LIPRIL 2.5MG,5MG,10MG
LISCARD 2.5MG,5MG,10MG

LISORIL 2.5MG,5MG,10MG,20MG

LISOTEC 2.5MG,5MG

LISTRIL 2.5MG,5MG,10MG

NIVANT 2.5MG,5MG,10MG,20MG

ODACE 2.5MG,5MG,10MG

LIPRIL- H LISINOPRIL5MG + HYDROCHLOROTHIAZIDE 12.5MG

ENALAPRIL

CANVAS 2.5MG,5MG DILVAS 2.5MG,5MG

 ENACE
 2.5MG,5MG,10MG

 ENAM
 2.5MG,5MG,10MG

 ENAL
 2.5MG,5MG,10MG

 ENAPRIL
 2.5MG,5MG,10MG

ENLACARD 2.5MG,5MG,10MG NORMACE 2.5MG,5MG,10MG **MYOACE** 2.5MG,5MG,10MG **ENVAS** 2.5MG,5MG,10MG **HYTROL** 2.5MG,5MG,10MG **NURIL** 2.5MG,5MG,10MG **LUPINACE** 2.5MG,5MG,10MG **INVORIL** 2.5MG,5MG,10MG

CAPTOPRIL

ACETEN 12.5MG,25MG CAPTOPRIL 12.5MG,25MG

CAPTOPRIL-H CAPTOPRIL25+HYDROCHLOROTHIAZIDE25MG

RAMIPRIL

CARDACE 1.25MG,2.5MG,5MG,10MG

CORPRIL 1.25MG,2.5MG,5MG

RAMACE 1.25MG,2.5MG,5MG,10MG

CARDACE-H HYDROCHLOROTHIAZIDE12.5MG+RAMIPRIL2.5MG
RAMACE-H HYDROCHLOROTHIAZIDE12.5MG+RAMIPRIL2.5MG

STAMACE RAMIPRIL2.5MG+AMLODIPINE5MG

DIURETICS

FUROSEMIDE (LOOP DIURETIC)

LASIX 40MG

LOOP DIURETIC + ALDOSTERONE BLOCKERS

AQUAMIDE FUROSEMIDE50MG+SPIRONOLACTONE20MG
FRUSELAC FUROSEMIDE20MG+SPIRONOLACTONE50MG
FRUSELAC-DS FUROSEMIDE40MG+SPIRONOLACTONE50MG
LASILACTONE FUROSEMIDE20MG+SPIRONOLACTONE50MG
SPIROMIDE SPIRONOLACTONE50MG+FUROSEMIDE20MG
SPIROTIC FUROSEMIDE20MG+SPIRONOLACTONE50MG

FRUSEMIDE +AMILORIDE

AMIFRU-40 FUROSEMIDE40MG+AMILORIDE5MG
AMIMIDE FUROSEMIDE40MG+AMILORIDE5MG
LASIRIDE FUROSEMIDE40MG+AMILORIDE HCL5MG

TORSEMIDE (LOOP DIURETIC)

DEMATOR 10MG,20MG

DIUTOR 5MG,10MG,20MG,100MG
DYAMIDE 5MG,10MG,20MG,100MG
TORGET 5MG,10MG,20MG,40MG,100MG

TORIDE 10MG,20MG,100MG

TORSEMI 10MG,20MG

ZATOR 5MG,10MG,20MG,100MG

DYTOR PLUS TORASEMIDE10MG+SPIRONOLACTONE50MG

DYTOR 5MG,10MG,20MG

HYDROCHLOROTHIAZIDES

AQUAZIDE 12.5MG,25MG BPZIDE 12.5MG,25MG HYDRIDE 12.5MG,25MG

KLORZIDE 25MG

XENIA 12.5MG,25MG

ALDOSTERONE BLOCKERS

SPIRONOLACTONE

ALDACTONE 25MG,50MG,100MG

ALDACTIDE SPIRONOLACTONE25MG+HYDROFLUMETHIAZIDE25MG

SPILACTONE-T SPIRONOLACTONE100MG+TORASEMIDE10MG

EPLERENONE

EPLERAN 25MG

EPTUS 25MG,50MG EXINIA 25MG,50MG

DIGOXIN

LANOXIN 0.25MG DIGOX 0.25MG

CELOXIN 0.25MG,SYP-1.5MG

SANGOXIN 0.25MG